Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Shiho Arima

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111946956, A5112960234. Sources: OpenAlex.

Their work

Papers
35
Trials
0
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 9 papers · 2024: 4 papers · 2025: 6 papers · 2026: 7 papers

Papers 35

  1. Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folini… Co-author DOI 10.1002/ijc.70072↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Co-author DOI 10.1111/ajco.70041↗
  4. Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluor… Co-author DOI 10.1177/17588359261442386↗
  5. Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic ac… Co-author DOI 10.1186/s12885-026-16237-2↗
  6. Dynamic analysis of C-reactive protein/albumin ratio in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-8417823/v1↗
  7. Aldehyde Dehydrogenase 2 Activity Assessed Using the Acetaldehyde Breath Test Is Associated with Benign Pancreatic Disease and Pancreatic Cancer: A Case-Contro… Co-author DOI 10.3390/jcm15197543↗
  8. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… Co-author DOI 10.1016/j.esmogo.2025.100150↗
  9. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  10. Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from … Co-author DOI 10.1177/17588359251320768↗
  11. Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of dat… Co-author DOI 10.1177/17588359251393156↗
  12. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Co-author DOI 10.1186/s12885-025-14992-2↗
  13. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Co-author DOI 10.3389/fonc.2025.1626689↗
  14. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or ge… Co-author DOI 10.1038/s41598-024-55673-7↗
  15. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  16. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  17. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  18. Efficacy and safety of a novel anti-reflux metal stent during neoadjuvant chemotherapy for pancreatic cancer: A prospective multicenter exploratory study. Co-author DOI 10.1002/jhbp.1239↗
  19. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study. Co-author DOI 10.1007/s10147-023-02354-6↗
  20. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-… Co-author DOI 10.1038/s41598-023-34962-7↗
  21. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
  22. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study. Co-author DOI 10.1159/000527176↗
  23. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗
  24. Focal Type 2 Autoimmune Pancreatitis Mimicking Pancreatic Cancer: Treatment with Neoadjuvant Chemotherapy and Surgery. Co-author DOI 10.2169/internalmedicine.0224-22↗
  25. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel. Co-author DOI 10.21873/anticanres.16335↗
  26. Next-Generation Sequencing Analysis of Pancreatic Cancer Using Residual Liquid Cytology Specimens from Endoscopic Ultrasound-Guided Fine-Needle Biopsy: A Prosp… Co-author DOI 10.3390/diagnostics13061078↗
  27. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAP… Co-author DOI 10.1016/j.jgo.2021.06.011↗
  28. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  29. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multi… Co-author DOI 10.1186/s12885-021-09139-y↗
  30. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗
  31. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). Co-author DOI 10.1097/mpa.0000000000001859↗
  32. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection. Co-author DOI 10.21873/anticanres.15145↗
  33. Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal ade… Co-author DOI 10.1007/s00330-019-06517-w↗
  34. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.07.009↗
  35. Estimation of Extracellular Volume Fraction With Routine Multiphasic Pancreatic Computed Tomography to Predict the Survival of Patients With Stage IV Pancreati… Co-author DOI 10.1097/mpa.0000000000001427↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 25 shared papers, 2021–2026 · strength 3.76
  2. Kenji Mitsugi · 25 shared papers, 2021–2026 · strength 3.76
  3. Futa Koga · 25 shared papers, 2021–2026 · strength 3.76
  4. Mototsugu Shimokawa · 25 shared papers, 2021–2026 · strength 3.76
  5. Taiga Otsuka · 25 shared papers, 2021–2026 · strength 3.76
  6. Tsuyoshi Shirakawa · 25 shared papers, 2021–2026 · strength 3.76
  7. Hiroki Taguchi · 25 shared papers, 2021–2026 · strength 3.76
  8. Taro Shibuki · 21 shared papers, 2021–2026 · strength 2.96
  9. Azusa Komori · 21 shared papers, 2021–2026 · strength 2.96
  10. Yasunori Kawaguchi · 16 shared papers, 2021–2026 · strength 2.60
  11. Yasushi Ide · 17 shared papers, 2021–2026 · strength 2.48
  12. Kazuo Nishikawa · 14 shared papers, 2023–2026 · strength 2.38
  13. Shuji Arita · 14 shared papers, 2023–2026 · strength 2.38
  14. Masaru Fukahori · 14 shared papers, 2021–2025 · strength 1.85
  15. Keisuke Miwa · 11 shared papers, 2023–2026 · strength 1.72
  16. Norio Ureshino · 13 shared papers, 2021–2025 · strength 1.68
  17. Akio Ido · 10 shared papers, 2021–2026 · strength 1.44
  18. Yoshinobu Okabe · 7 shared papers, 2021–2024 · strength 0.91
  19. Shinichi Hashimoto · 5 shared papers, 2021–2026 · strength 0.85
  20. Makoto Hinokuchi · 4 shared papers, 2023–2026 · strength 0.75
  21. Tomonori Araki · 4 shared papers, 2025–2026 · strength 0.73
  22. Takao Ohtsuka · 3 shared papers, 2023–2026 · strength 0.57
  23. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  24. Yoshihiko Fukukura · 3 shared papers, 2019–2020 · strength 0.33
  25. Kosei Maemura · 3 shared papers, 2019–2020 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.